Veraxa and OmniAb to develop bispecific ADC tumour programme
Veraxa Biotech has recently announced a groundbreaking joint discovery partnership with OmniAb to develop a bispecific antibody drug conjugate (bsADC) programme targeted at solid tumors. This partnership brings together OmniAb’s transgenic antibody discovery solutions with Veraxa’s ADC linker technology and conjugation expertise, creating a powerful platform for next-generation therapeutic discovery.
The bsADC programme initiated by Veraxa will focus on targeting two specific molecules in cancer medicine. Leveraging OmniAb’s transgenic antibody discovery solutions, Veraxa aims to acquire high-quality human antibody leads that will undergo natural optimization through in vivo affinity maturation. Following this, Veraxa will utilize its proprietary linker technology and conjugation approach to develop the bsADC lead candidate and oversee the preclinical validation process.
Both Veraxa and OmniAb will co-own the resulting bsADC programme, sharing future revenues generated from its further development, licensing, and commercialization. Veraxa’s co-founder and CEO, Christoph Antz, expressed excitement about the partnership, stating that it merges two complementary technologies to create a new class of bispecific ADCs. This collaboration aligns with Veraxa’s mission to drive innovation through strategic partnerships and underscores the company’s commitment to developing novel therapeutics for challenging diseases like solid tumors.
Veraxa Biotech specializes in the discovery and development of antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other formats. The company is advancing its ADC pipeline and BiTAC formats towards clinical development, leveraging cutting-edge technologies and adhering to quality-by-design principles.
In a significant development, Veraxa Biotech is set to go public in the United States through a merger with Voyager Acquisition Corp, a healthcare special purpose acquisition company. The deal, expected to close in the fourth quarter of 2025, will provide Veraxa with additional resources to further advance its innovative drug discovery programs.
The collaboration between Veraxa and OmniAb to develop a bispecific ADC tumor programme represents a major milestone in the field of cancer therapeutics. By combining their expertise and technologies, the two companies are poised to make significant strides in addressing the unmet medical needs of patients with solid tumors. This exciting partnership underscores Veraxa’s commitment to driving innovation and advancing novel treatment options for cancer patients worldwide.
